Lonza Group AG Stock

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Market Closed - Swiss Exchange 11:30:06 2024-06-14 EDT 5-day change 1st Jan Change
480.3 CHF -0.17% Intraday chart for Lonza Group AG -3.98% +35.79%

Financials

Sales 2024 * 6.66B 7.48B 10.27B Sales 2025 * 7.62B 8.56B 11.76B Capitalization 34.64B 38.9B 53.41B
Net income 2024 * 893M 1B 1.38B Net income 2025 * 1.11B 1.24B 1.71B EV / Sales 2024 * 5.61 x
Net Debt 2024 * 2.72B 3.05B 4.19B Net Debt 2025 * 3.32B 3.73B 5.12B EV / Sales 2025 * 4.98 x
P/E ratio 2024 *
38.8 x
P/E ratio 2025 *
31 x
Employees 18,000
Yield 2024 *
0.95%
Yield 2025 *
1.11%
Free-Float 96.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.17%
1 week-3.98%
Current month-1.25%
1 month-5.34%
3 months-0.62%
6 months+44.67%
Current year+35.79%
More quotes
1 week
473.70
Extreme 473.7
504.20
1 month
473.70
Extreme 473.7
533.40
Current year
339.00
Extreme 339
559.40
1 year
308.60
Extreme 308.6
574.60
3 years
308.60
Extreme 308.6
785.40
5 years
301.00
Extreme 301
785.40
10 years
90.90
Extreme 90.9
785.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 17-04-24
Director of Finance/CFO 52 21-11-30
Chief Operating Officer 55 22-07-31
Members of the board TitleAgeSince
Director/Board Member 63 14-04-15
Director/Board Member 66 14-04-15
Director/Board Member 58 22-05-04
More insiders
Date Price Change Volume
24-06-14 480.3 -0.17% 178,783
24-06-13 481.1 -0.82% 186,943
24-06-12 485.1 -2.02% 341,121
24-06-11 495.1 -1.18% 156,282
24-06-10 501 +0.16% 118,736

Delayed Quote Swiss Exchange, June 14, 2024 at 11:30 am

More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
480.3 CHF
Average target price
583.7 CHF
Spread / Average Target
+21.53%
Consensus